Pharmaceuticals

Shen Lian Biomedical

Shen Lian Biomedical released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 62.6 M, actual EPS CNY 0

Shen Lian Biomedical to Release FY2025 Earnings on April 29 Pre-Market (BJT), Forecast Revenue CNY 571 M, EPS CNY 0.34

Shen Lian Biomedical FY2026 Q1 Earnings Release on April 29 After-Market BJT

Shen Lian Biomedical released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 50.57 M, actual EPS CNY 0

Shen Lian Biomedical released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue CNY 288.27 M (forecast CNY 571 M), actual EPS CNY -0.05 (forecast CNY 0.34)

Shen Lian Biomedical released FY2025 Q3 earnings on October 26 After-Market BJT, actual revenue CNY 115.97 M, actual EPS CNY 0.032

Shen Lian Biomedical released FY2025 9 Months earnings on October 26 After-Market (BJT), actual revenue CNY 237.69 M, actual EPS CNY -0.0277

Shen Lian Biomedical to Release FY2025 Q3 Earnings on October 23 After-Market BJT

Shen Lian Biomedical released FY2025 Q2 earnings on August 29 After-Market BJT, actual revenue CNY 42.98 M, actual EPS CNY -0.0177

Shen Lian Biomedical released FY2025 Semi-Annual Earnings on August 29 After-Market (BJT), Actual Revenue: CNY 121.73 M, Actual EPS: CNY -0.03

Shen Lian Biomedical to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Shenlian Biotech Approved for Swine Fever Gene Engineering Subunit Vaccine

Shenlian Bio Obtains Approval to Produce Swine Fever Vaccine

Shenlian Bio repurchased shares for a total of 20 million yuan

Shenlian Bio Inc. Q1 2025 Net Loss Widened

Shen Lian Biomedical released FY2025 Q1 earnings on April 29, 2025, after-market BJT with actual revenue of CNY 78.74 M and EPS of CNY -0.01

Shen Lian Biomedical to Release FY2025 Q1 Earnings Report on April 30 After-Market BJT

Shen Lian Biomedical to release FY2024 earnings on April 30 After-Market (BJT), forecast revenue CNY 478 M, EPS CNY 0.3

Shen Lian Biomedical released FY2024 Q4 earnings on February 27 After-Market (BJT), actual revenue CNY 55.11 M, actual EPS CNY -0.1427

Shen Lian Biomedical released FY2024 earnings on February 27 After-Market (BJT), actual revenue CNY 303.41 M (forecast CNY 478 M), actual EPS CNY -0.11 (forecast CNY 0.3)

688098

According to the Zhitong Finance APP, Shen Lian Biomedical disclosed its third-quarter report for 2025. The company achieved revenue of 238 million yuan in the first three quarters, a year-on-year decrease of 4.27%; the net profit attributable to the parent company was 280,000 yuan, turning from a loss to a profit year-on-year; the net profit excluding non-recurring items was a loss of 5.1 million yuan; the basic earnings per share were 0 yuan

Zhitong

Shen Lian Biomedical released its performance for the first three quarters, with a net profit attributable to the parent company of 280,000 yuan, turning a profit compared to the same period last year

Shen Lian Biomedical announced that United BioPharma, Inc. (UBI) plans to reduce its holdings by no more than 3% within the next three months to raise funds for the clinical trials and commercialization of an Alzheimer's vaccine. The specific reduction methods include reducing 4.1064 million shares through centralized bidding and reducing 8.2129 million shares through block trading

Shen Lian Biomedical: UBI plans to reduce its holdings by no more than 3% of shares

300683

002004

300204

603367

300878

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

HITECK

HUAPONT LIFE SCIENCES

Staidson BioPharm

CISEN

WECOME

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

Shen Lian Biomedical has been approved to produce a bivalent inactivated vaccine for swine streptococcosis and infectious pleuropneumonia, with the approval number issued by the Ministry of Agriculture and Rural Affairs. This product will enhance the company's product matrix for veterinary bacterial disease prevention and control, improve capacity utilization, and provide a more comprehensive epidemic prevention and control solution

Shen Lian Biomedical has been approved for a veterinary drug product approval number

On August 31, Shen Lian Biomedical announced that its investee company, Shizhiyuan, has completed the enrollment of 145 subjects in the Phase II clinical study of the innovative drug UB-221 injection. The marketing authorization and commercialization rights of UB-221 in mainland China are owned by Shizhiyuan. This drug is developed by United Biomedical, Inc. in the United States and is a subcutaneous injection formulation of a humanized original monoclonal antibody targeting anti-IgE therapy

Shen Lian Biomedical: The Phase II clinical study of the innovative drug UB-221 injection has completed the enrollment of all subjects

Shen Lian Biomedical announced that its operating revenue in the first half of 2025 was 122 million yuan, a year-on-year decrease of 3.68%. The net loss attributable to shareholders of the listed company was 12.8697 million yuan, compared to a net loss of 34.508 million yuan in the same period last year

Shen Lian Biomedical: Net loss of 12.8697 million yuan in the first half of 2025

600590

600218

At the close of trading on August 19, the Shanghai Composite Index rose by 0.3%, the Shenzhen Component Index rose by 0.3%, and the ChiNext Index rose by 0.39%. The market experienced a pullback after an early surge, with diesel generator concept stocks performing strongly, including QCEC and Tellhow hitting the daily limit. Pharmaceutical stocks collectively strengthened, with over ten stocks including Jimin Health and Shen Lian Biomedical reaching the daily limit. CPO concept stocks continued to show strength, with Cambridge Technology hitting the daily limit and Tianfu Communication rising over 10%. The military industry sector adjusted, with Guangqi Technology falling over 5%

Wallstreetcn

Tellhow

QCEC

August 19th Midday Review: Shanghai Composite Index rises 0.3% in half a day, pharmaceutical stocks strengthen collectively

According to the Zhitong Finance APP, Shen Lian Biomedical announced that the cumulative deviation value of the closing price increase of its stock has exceeded 30% for three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. The company stated that its current main business is veterinary biological products, and the innovative drug pipeline for AIDS monoclonal antibodies is independently operated by its joint venture company Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), which has characteristics of long R&D cycles, large investments, and high R&D risks

Shen Lian Biomedical: The innovative drug pipeline including monoclonal antibodies for AIDS is independently operated by Shizhiyuan

Shen Lian Biomedical Co., Ltd. announced that there has been an abnormal fluctuation in its stock price recently, with an increase of over 30%. After self-examination, the company confirmed that its production and operations are normal, and there are no undisclosed significant matters. The company is focusing on its innovative drug business and is increasing capital through its subsidiaries to layout in the field of human innovative drugs. It reminds investors to pay attention to research and development risks as well as market trading risks, and to invest rationally

Shen Lian Biomedical: The company's production and operations are normal, with no undisclosed significant matters that need to be disclosed

688336

300049

300199

688621

688091

In the morning session, the innovative drug concept became active again, with Shen Lian Biomedical hitting a two-day limit-up, Furui Co., Ltd. reaching a 20% limit-up, and HYBIO, Sun-Novo, SHANGHAI YIZHONG, and Sunshine Guojian Pharmaceutical rising over 5%. According to news, the "China Innovative Drug and Medical Device Multi-Payment White Paper" shows that the estimated scale of China's innovative drug and medical device market in 2024 is about 162 billion yuan. The white paper predicts that by 2035, the market size of innovative drugs and medical devices in China will exceed 1 trillion yuan

Sunshine Guojian Pharmaceutical

Furui Co.,Ltd.

HYBIO

Sun-Novo

SHANGHAI YIZHONG

The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

Shen Lian Biomedical(688098.SH)